1441848--3/31/2009--FACET_BIOTECH

related topics

{product, candidate, development}

{product, liability, claim}

{stock, price, operating}

{property, intellectual, protect}

{control, financial, internal}

{cost, regulation, environmental}

{acquisition, growth, future}

{tax, income, asset}

{personnel, key, retain}

{provision, law, control}

{financial, litigation, operation}

{stock, price, share}

If our research and development efforts are not successful, we may not be able to effectively develop new products. Our business strategy is dependent on our ability to in-license or otherwise acquire the rights to develop and commercialize products. Unless our clinical studies demonstrate the safety and efficacy of our product candidates, we will not be able to commercialize our product candidates. The clinical development of drug products is inherently uncertain and expensive and subject to extensive government regulation. We may be unable to enroll a sufficient number of patients in a timely manner in order to complete our clinical trials. If our collaborations are not successful or are terminated by our collaborators, we may not effectively develop and market some of our product candidates. We must protect our patent and other intellectual property rights to succeed. We may need to obtain patent licenses from others in order to manufacture or sell our potential products and we may not be able to obtain these licenses on terms acceptable to us or at all. The failure to gain market acceptance of our product candidates among the medical community would adversely affect any product revenue we may receive in the future. Changes in the U.S. and international health care industry, including regarding reimbursement rates, could adversely affect the commercial value of our development product candidates. We may be unable to obtain or maintain regulatory approval for our products. We rely on sole source, third parties to manufacture our products. Manufacturing changes may result in delays in obtaining regulatory approval or marketing for our products. We must comply with extensive government regulations and laws. We may incur significant costs in order to comply with environmental regulations or to defend claims arising from accidents involving the use of hazardous materials. We may be subject to product liability claims, and our insurance coverage may not be adequate to cover these claims. We may be required to satisfy certain indemnification obligations to PDL or may not be able to collect on indemnification rights from PDL. We must attract and retain highly skilled employees in order to succeed. We anticipate that we will incur losses for the foreseeable future. We may never achieve or sustain profitability. If additional capital is not available, we may have to curtail or cease operations. We may obtain future financing through the issuance of debt or equity, which may have an adverse effect on our stockholders or may otherwise adversely affect our business. We may not receive the contingent consideration related to the sale of the product rights to new formulations of Cardene and the ularitide development-stage product under the Asset Purchase Agreement with EKR. We have no history operating as an independent company upon which you can evaluate us. Our historical financial information is not necessarily indicative of our future financial position, future results of operations or future cash flows and may not reflect what our financial position, results of operations or cash flows would have been as a stand-alone company during the periods presented. Our operating expenses and results and any future revenue likely will fluctuate in future periods. The market price for our shares may fluctuate widely. Your percentage ownership in Facet Biotech may be diluted in the future. Provisions in our certificate of incorporation and bylaws and of Delaware law may prevent or delay an acquisition of our company, which could decrease the trading price of our common stock.

Full 10-K form ▸

1441848--3/31/2009--FACET_BIOTECH_CORP